Loading…
Secondary bile acids improve risk prediction for non‐invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease
Background Dysregulated bile acid (BA) metabolism has been linked to steatosis, inflammation, and fibrosis in nonalcoholic fatty liver disease (NAFLD). Aim To determine whether circulating BA levels accurately stage liver fibrosis in NAFLD. Methods We recruited 550 Chinese adults with biopsy‐proven...
Saved in:
Published in: | Alimentary pharmacology & therapeutics 2023-04, Vol.57 (8), p.872-885 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4442-8c0ad6cef56eea2fc5aa4b320362c323cb1d3d0eb9b10d32d7cfe7951ad92cb3 |
---|---|
cites | cdi_FETCH-LOGICAL-c4442-8c0ad6cef56eea2fc5aa4b320362c323cb1d3d0eb9b10d32d7cfe7951ad92cb3 |
container_end_page | 885 |
container_issue | 8 |
container_start_page | 872 |
container_title | Alimentary pharmacology & therapeutics |
container_volume | 57 |
creator | Liu, A‐Na Xu, Cui‐Fang Liu, Ya‐Ru Sun, Dan‐Qin Jiang, Ling Tang, Liang‐Jie Zhu, Pei‐Wu Chen, Sui‐Dan Liu, Wen‐Yue Wang, Xiao‐Dong Targher, Giovanni Byrne, Christopher D. Wong, Vincent Wai‐Sun Fu, Junfen Su, Ming‐Ming Loomba, Rohit Zheng, Ming‐Hua Ni, Yan |
description | Background
Dysregulated bile acid (BA) metabolism has been linked to steatosis, inflammation, and fibrosis in nonalcoholic fatty liver disease (NAFLD).
Aim
To determine whether circulating BA levels accurately stage liver fibrosis in NAFLD.
Methods
We recruited 550 Chinese adults with biopsy‐proven NAFLD and varying levels of fibrosis. Ultra‐performance liquid chromatography coupled with tandem mass spectrometry was performed to quantify 38 serum BAs.
Results
Compared to those without fibrosis, patients with mild fibrosis (stage F1) had significantly higher levels of secondary BAs, and increased diastolic blood pressure (DBP), alanine aminotransferase (ALT), body mass index, and waist circumstance (WC). The combination of serum BAs with WC, DBP, ALT, or Homeostatic Model Assessment for Insulin Resistance performed well in identifying mild fibrosis, in men and women, and in those with/without obesity, with AUROCs 0.80, 0.88, 0.75 and 0.78 in the training set (n = 385), and 0.69, 0.80, 0.61 and 0.69 in the testing set (n = 165), respectively. In comparison, the combination of BAs and clinical/biochemical biomarkers performed less well in identifying significant fibrosis (F2‐4). In women and in non‐obese subjects, AUROCs were 0.75 and 0.71 in the training set, 0.65 and 0.66 in the validation set, respectively. However, these AUROCs were higher than those observed for the fibrosis‐4 index, NAFLD fibrosis score, and Hepamet fibrosis score.
Conclusions
Secondary BA levels were significantly increased in NAFLD, especially in those with mild fibrosis. The combination of serum BAs and clinical/biochemical biomarkers for identifying mild fibrosis merits further assessment.
Secondary bile acids were significantly increased in NAFLD, especially in those with mild fibrosis. The combination of serum bile acids and clinical/biochemical biomarkers for identifying mild fibrosis is worthy of further assessment. |
doi_str_mv | 10.1111/apt.17362 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10792530</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2768244199</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4442-8c0ad6cef56eea2fc5aa4b320362c323cb1d3d0eb9b10d32d7cfe7951ad92cb3</originalsourceid><addsrcrecordid>eNp1kc1u1DAUhS0EokNhwQsgS2xgkdY_iTNZoaoqP1IlkJi95djX9BYnDnZmqtmx7Y5n5EnwdIYKkPDGlu7no3PPIeQ5Zye8nFMzzSe8lUo8IAsuVVMJJtVDsmBCdZVYcnlEnuR8zRhTLROPyZFU5cEUW5Dbz2Dj6Eza0h4DUGPRZYrDlOIGaML8lU4JHNoZ40h9THSM48_vP3DcmIwFQQfjjB6tuSOipwMGR0OZJeqxTzFjERx3_0yw8SoGtNSbed4eIIcZTIan5JE3IcOzw31MVm8vVufvq8uP7z6cn11Wtq5rUS0tM05Z8I0CMMLbxpi6l7uNhZVC2p476Rj0Xc-Zk8K11kPbNdy4TtheHpM3e9lp3Q_gbHGfTNBTwqGEoKNB_fdkxCv9JW40Z20nGsmKwquDQorf1pBnPWC2EIIZIa6zFq1airrmXVfQl_-g13GdSg47atm1SrFaFur1nrIlrJzA37vhTO8K1qVgfVdwYV_8af-e_N1oAU73wE2pc_t_JX32abWX_AVNQrVU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2789766043</pqid></control><display><type>article</type><title>Secondary bile acids improve risk prediction for non‐invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Liu, A‐Na ; Xu, Cui‐Fang ; Liu, Ya‐Ru ; Sun, Dan‐Qin ; Jiang, Ling ; Tang, Liang‐Jie ; Zhu, Pei‐Wu ; Chen, Sui‐Dan ; Liu, Wen‐Yue ; Wang, Xiao‐Dong ; Targher, Giovanni ; Byrne, Christopher D. ; Wong, Vincent Wai‐Sun ; Fu, Junfen ; Su, Ming‐Ming ; Loomba, Rohit ; Zheng, Ming‐Hua ; Ni, Yan</creator><creatorcontrib>Liu, A‐Na ; Xu, Cui‐Fang ; Liu, Ya‐Ru ; Sun, Dan‐Qin ; Jiang, Ling ; Tang, Liang‐Jie ; Zhu, Pei‐Wu ; Chen, Sui‐Dan ; Liu, Wen‐Yue ; Wang, Xiao‐Dong ; Targher, Giovanni ; Byrne, Christopher D. ; Wong, Vincent Wai‐Sun ; Fu, Junfen ; Su, Ming‐Ming ; Loomba, Rohit ; Zheng, Ming‐Hua ; Ni, Yan</creatorcontrib><description>Background
Dysregulated bile acid (BA) metabolism has been linked to steatosis, inflammation, and fibrosis in nonalcoholic fatty liver disease (NAFLD).
Aim
To determine whether circulating BA levels accurately stage liver fibrosis in NAFLD.
Methods
We recruited 550 Chinese adults with biopsy‐proven NAFLD and varying levels of fibrosis. Ultra‐performance liquid chromatography coupled with tandem mass spectrometry was performed to quantify 38 serum BAs.
Results
Compared to those without fibrosis, patients with mild fibrosis (stage F1) had significantly higher levels of secondary BAs, and increased diastolic blood pressure (DBP), alanine aminotransferase (ALT), body mass index, and waist circumstance (WC). The combination of serum BAs with WC, DBP, ALT, or Homeostatic Model Assessment for Insulin Resistance performed well in identifying mild fibrosis, in men and women, and in those with/without obesity, with AUROCs 0.80, 0.88, 0.75 and 0.78 in the training set (n = 385), and 0.69, 0.80, 0.61 and 0.69 in the testing set (n = 165), respectively. In comparison, the combination of BAs and clinical/biochemical biomarkers performed less well in identifying significant fibrosis (F2‐4). In women and in non‐obese subjects, AUROCs were 0.75 and 0.71 in the training set, 0.65 and 0.66 in the validation set, respectively. However, these AUROCs were higher than those observed for the fibrosis‐4 index, NAFLD fibrosis score, and Hepamet fibrosis score.
Conclusions
Secondary BA levels were significantly increased in NAFLD, especially in those with mild fibrosis. The combination of serum BAs and clinical/biochemical biomarkers for identifying mild fibrosis merits further assessment.
Secondary bile acids were significantly increased in NAFLD, especially in those with mild fibrosis. The combination of serum bile acids and clinical/biochemical biomarkers for identifying mild fibrosis is worthy of further assessment.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/apt.17362</identifier><identifier>PMID: 36670060</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adult ; Alanine transaminase ; Bile acids ; Bile Acids and Salts ; Biomarkers ; Biopsy ; Blood pressure ; Body mass index ; Fatty liver ; Female ; Fibrosis ; Humans ; Inflammation - complications ; Insulin ; Insulin resistance ; Liquid chromatography ; Liver - pathology ; Liver Cirrhosis - complications ; Liver diseases ; liver fibrosis ; Male ; Mass spectroscopy ; Non-alcoholic Fatty Liver Disease - complications ; nonalcoholic fatty liver disease ; Obesity ; Obesity - complications ; risk prediction ; secondary bile acids ; Steatosis</subject><ispartof>Alimentary pharmacology & therapeutics, 2023-04, Vol.57 (8), p.872-885</ispartof><rights>2023 John Wiley & Sons Ltd.</rights><rights>Copyright © 2023 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4442-8c0ad6cef56eea2fc5aa4b320362c323cb1d3d0eb9b10d32d7cfe7951ad92cb3</citedby><cites>FETCH-LOGICAL-c4442-8c0ad6cef56eea2fc5aa4b320362c323cb1d3d0eb9b10d32d7cfe7951ad92cb3</cites><orcidid>0000-0003-1779-7266 ; 0000-0002-4845-9991 ; 0000-0002-4325-3900 ; 0000-0003-4984-2631 ; 0000-0003-2215-9410</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36670060$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, A‐Na</creatorcontrib><creatorcontrib>Xu, Cui‐Fang</creatorcontrib><creatorcontrib>Liu, Ya‐Ru</creatorcontrib><creatorcontrib>Sun, Dan‐Qin</creatorcontrib><creatorcontrib>Jiang, Ling</creatorcontrib><creatorcontrib>Tang, Liang‐Jie</creatorcontrib><creatorcontrib>Zhu, Pei‐Wu</creatorcontrib><creatorcontrib>Chen, Sui‐Dan</creatorcontrib><creatorcontrib>Liu, Wen‐Yue</creatorcontrib><creatorcontrib>Wang, Xiao‐Dong</creatorcontrib><creatorcontrib>Targher, Giovanni</creatorcontrib><creatorcontrib>Byrne, Christopher D.</creatorcontrib><creatorcontrib>Wong, Vincent Wai‐Sun</creatorcontrib><creatorcontrib>Fu, Junfen</creatorcontrib><creatorcontrib>Su, Ming‐Ming</creatorcontrib><creatorcontrib>Loomba, Rohit</creatorcontrib><creatorcontrib>Zheng, Ming‐Hua</creatorcontrib><creatorcontrib>Ni, Yan</creatorcontrib><title>Secondary bile acids improve risk prediction for non‐invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Background
Dysregulated bile acid (BA) metabolism has been linked to steatosis, inflammation, and fibrosis in nonalcoholic fatty liver disease (NAFLD).
Aim
To determine whether circulating BA levels accurately stage liver fibrosis in NAFLD.
Methods
We recruited 550 Chinese adults with biopsy‐proven NAFLD and varying levels of fibrosis. Ultra‐performance liquid chromatography coupled with tandem mass spectrometry was performed to quantify 38 serum BAs.
Results
Compared to those without fibrosis, patients with mild fibrosis (stage F1) had significantly higher levels of secondary BAs, and increased diastolic blood pressure (DBP), alanine aminotransferase (ALT), body mass index, and waist circumstance (WC). The combination of serum BAs with WC, DBP, ALT, or Homeostatic Model Assessment for Insulin Resistance performed well in identifying mild fibrosis, in men and women, and in those with/without obesity, with AUROCs 0.80, 0.88, 0.75 and 0.78 in the training set (n = 385), and 0.69, 0.80, 0.61 and 0.69 in the testing set (n = 165), respectively. In comparison, the combination of BAs and clinical/biochemical biomarkers performed less well in identifying significant fibrosis (F2‐4). In women and in non‐obese subjects, AUROCs were 0.75 and 0.71 in the training set, 0.65 and 0.66 in the validation set, respectively. However, these AUROCs were higher than those observed for the fibrosis‐4 index, NAFLD fibrosis score, and Hepamet fibrosis score.
Conclusions
Secondary BA levels were significantly increased in NAFLD, especially in those with mild fibrosis. The combination of serum BAs and clinical/biochemical biomarkers for identifying mild fibrosis merits further assessment.
Secondary bile acids were significantly increased in NAFLD, especially in those with mild fibrosis. The combination of serum bile acids and clinical/biochemical biomarkers for identifying mild fibrosis is worthy of further assessment.</description><subject>Adult</subject><subject>Alanine transaminase</subject><subject>Bile acids</subject><subject>Bile Acids and Salts</subject><subject>Biomarkers</subject><subject>Biopsy</subject><subject>Blood pressure</subject><subject>Body mass index</subject><subject>Fatty liver</subject><subject>Female</subject><subject>Fibrosis</subject><subject>Humans</subject><subject>Inflammation - complications</subject><subject>Insulin</subject><subject>Insulin resistance</subject><subject>Liquid chromatography</subject><subject>Liver - pathology</subject><subject>Liver Cirrhosis - complications</subject><subject>Liver diseases</subject><subject>liver fibrosis</subject><subject>Male</subject><subject>Mass spectroscopy</subject><subject>Non-alcoholic Fatty Liver Disease - complications</subject><subject>nonalcoholic fatty liver disease</subject><subject>Obesity</subject><subject>Obesity - complications</subject><subject>risk prediction</subject><subject>secondary bile acids</subject><subject>Steatosis</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp1kc1u1DAUhS0EokNhwQsgS2xgkdY_iTNZoaoqP1IlkJi95djX9BYnDnZmqtmx7Y5n5EnwdIYKkPDGlu7no3PPIeQ5Zye8nFMzzSe8lUo8IAsuVVMJJtVDsmBCdZVYcnlEnuR8zRhTLROPyZFU5cEUW5Dbz2Dj6Eza0h4DUGPRZYrDlOIGaML8lU4JHNoZ40h9THSM48_vP3DcmIwFQQfjjB6tuSOipwMGR0OZJeqxTzFjERx3_0yw8SoGtNSbed4eIIcZTIan5JE3IcOzw31MVm8vVufvq8uP7z6cn11Wtq5rUS0tM05Z8I0CMMLbxpi6l7uNhZVC2p476Rj0Xc-Zk8K11kPbNdy4TtheHpM3e9lp3Q_gbHGfTNBTwqGEoKNB_fdkxCv9JW40Z20nGsmKwquDQorf1pBnPWC2EIIZIa6zFq1airrmXVfQl_-g13GdSg47atm1SrFaFur1nrIlrJzA37vhTO8K1qVgfVdwYV_8af-e_N1oAU73wE2pc_t_JX32abWX_AVNQrVU</recordid><startdate>202304</startdate><enddate>202304</enddate><creator>Liu, A‐Na</creator><creator>Xu, Cui‐Fang</creator><creator>Liu, Ya‐Ru</creator><creator>Sun, Dan‐Qin</creator><creator>Jiang, Ling</creator><creator>Tang, Liang‐Jie</creator><creator>Zhu, Pei‐Wu</creator><creator>Chen, Sui‐Dan</creator><creator>Liu, Wen‐Yue</creator><creator>Wang, Xiao‐Dong</creator><creator>Targher, Giovanni</creator><creator>Byrne, Christopher D.</creator><creator>Wong, Vincent Wai‐Sun</creator><creator>Fu, Junfen</creator><creator>Su, Ming‐Ming</creator><creator>Loomba, Rohit</creator><creator>Zheng, Ming‐Hua</creator><creator>Ni, Yan</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1779-7266</orcidid><orcidid>https://orcid.org/0000-0002-4845-9991</orcidid><orcidid>https://orcid.org/0000-0002-4325-3900</orcidid><orcidid>https://orcid.org/0000-0003-4984-2631</orcidid><orcidid>https://orcid.org/0000-0003-2215-9410</orcidid></search><sort><creationdate>202304</creationdate><title>Secondary bile acids improve risk prediction for non‐invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease</title><author>Liu, A‐Na ; Xu, Cui‐Fang ; Liu, Ya‐Ru ; Sun, Dan‐Qin ; Jiang, Ling ; Tang, Liang‐Jie ; Zhu, Pei‐Wu ; Chen, Sui‐Dan ; Liu, Wen‐Yue ; Wang, Xiao‐Dong ; Targher, Giovanni ; Byrne, Christopher D. ; Wong, Vincent Wai‐Sun ; Fu, Junfen ; Su, Ming‐Ming ; Loomba, Rohit ; Zheng, Ming‐Hua ; Ni, Yan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4442-8c0ad6cef56eea2fc5aa4b320362c323cb1d3d0eb9b10d32d7cfe7951ad92cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>Alanine transaminase</topic><topic>Bile acids</topic><topic>Bile Acids and Salts</topic><topic>Biomarkers</topic><topic>Biopsy</topic><topic>Blood pressure</topic><topic>Body mass index</topic><topic>Fatty liver</topic><topic>Female</topic><topic>Fibrosis</topic><topic>Humans</topic><topic>Inflammation - complications</topic><topic>Insulin</topic><topic>Insulin resistance</topic><topic>Liquid chromatography</topic><topic>Liver - pathology</topic><topic>Liver Cirrhosis - complications</topic><topic>Liver diseases</topic><topic>liver fibrosis</topic><topic>Male</topic><topic>Mass spectroscopy</topic><topic>Non-alcoholic Fatty Liver Disease - complications</topic><topic>nonalcoholic fatty liver disease</topic><topic>Obesity</topic><topic>Obesity - complications</topic><topic>risk prediction</topic><topic>secondary bile acids</topic><topic>Steatosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, A‐Na</creatorcontrib><creatorcontrib>Xu, Cui‐Fang</creatorcontrib><creatorcontrib>Liu, Ya‐Ru</creatorcontrib><creatorcontrib>Sun, Dan‐Qin</creatorcontrib><creatorcontrib>Jiang, Ling</creatorcontrib><creatorcontrib>Tang, Liang‐Jie</creatorcontrib><creatorcontrib>Zhu, Pei‐Wu</creatorcontrib><creatorcontrib>Chen, Sui‐Dan</creatorcontrib><creatorcontrib>Liu, Wen‐Yue</creatorcontrib><creatorcontrib>Wang, Xiao‐Dong</creatorcontrib><creatorcontrib>Targher, Giovanni</creatorcontrib><creatorcontrib>Byrne, Christopher D.</creatorcontrib><creatorcontrib>Wong, Vincent Wai‐Sun</creatorcontrib><creatorcontrib>Fu, Junfen</creatorcontrib><creatorcontrib>Su, Ming‐Ming</creatorcontrib><creatorcontrib>Loomba, Rohit</creatorcontrib><creatorcontrib>Zheng, Ming‐Hua</creatorcontrib><creatorcontrib>Ni, Yan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, A‐Na</au><au>Xu, Cui‐Fang</au><au>Liu, Ya‐Ru</au><au>Sun, Dan‐Qin</au><au>Jiang, Ling</au><au>Tang, Liang‐Jie</au><au>Zhu, Pei‐Wu</au><au>Chen, Sui‐Dan</au><au>Liu, Wen‐Yue</au><au>Wang, Xiao‐Dong</au><au>Targher, Giovanni</au><au>Byrne, Christopher D.</au><au>Wong, Vincent Wai‐Sun</au><au>Fu, Junfen</au><au>Su, Ming‐Ming</au><au>Loomba, Rohit</au><au>Zheng, Ming‐Hua</au><au>Ni, Yan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Secondary bile acids improve risk prediction for non‐invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2023-04</date><risdate>2023</risdate><volume>57</volume><issue>8</issue><spage>872</spage><epage>885</epage><pages>872-885</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Background
Dysregulated bile acid (BA) metabolism has been linked to steatosis, inflammation, and fibrosis in nonalcoholic fatty liver disease (NAFLD).
Aim
To determine whether circulating BA levels accurately stage liver fibrosis in NAFLD.
Methods
We recruited 550 Chinese adults with biopsy‐proven NAFLD and varying levels of fibrosis. Ultra‐performance liquid chromatography coupled with tandem mass spectrometry was performed to quantify 38 serum BAs.
Results
Compared to those without fibrosis, patients with mild fibrosis (stage F1) had significantly higher levels of secondary BAs, and increased diastolic blood pressure (DBP), alanine aminotransferase (ALT), body mass index, and waist circumstance (WC). The combination of serum BAs with WC, DBP, ALT, or Homeostatic Model Assessment for Insulin Resistance performed well in identifying mild fibrosis, in men and women, and in those with/without obesity, with AUROCs 0.80, 0.88, 0.75 and 0.78 in the training set (n = 385), and 0.69, 0.80, 0.61 and 0.69 in the testing set (n = 165), respectively. In comparison, the combination of BAs and clinical/biochemical biomarkers performed less well in identifying significant fibrosis (F2‐4). In women and in non‐obese subjects, AUROCs were 0.75 and 0.71 in the training set, 0.65 and 0.66 in the validation set, respectively. However, these AUROCs were higher than those observed for the fibrosis‐4 index, NAFLD fibrosis score, and Hepamet fibrosis score.
Conclusions
Secondary BA levels were significantly increased in NAFLD, especially in those with mild fibrosis. The combination of serum BAs and clinical/biochemical biomarkers for identifying mild fibrosis merits further assessment.
Secondary bile acids were significantly increased in NAFLD, especially in those with mild fibrosis. The combination of serum bile acids and clinical/biochemical biomarkers for identifying mild fibrosis is worthy of further assessment.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>36670060</pmid><doi>10.1111/apt.17362</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0003-1779-7266</orcidid><orcidid>https://orcid.org/0000-0002-4845-9991</orcidid><orcidid>https://orcid.org/0000-0002-4325-3900</orcidid><orcidid>https://orcid.org/0000-0003-4984-2631</orcidid><orcidid>https://orcid.org/0000-0003-2215-9410</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0269-2813 |
ispartof | Alimentary pharmacology & therapeutics, 2023-04, Vol.57 (8), p.872-885 |
issn | 0269-2813 1365-2036 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10792530 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | Adult Alanine transaminase Bile acids Bile Acids and Salts Biomarkers Biopsy Blood pressure Body mass index Fatty liver Female Fibrosis Humans Inflammation - complications Insulin Insulin resistance Liquid chromatography Liver - pathology Liver Cirrhosis - complications Liver diseases liver fibrosis Male Mass spectroscopy Non-alcoholic Fatty Liver Disease - complications nonalcoholic fatty liver disease Obesity Obesity - complications risk prediction secondary bile acids Steatosis |
title | Secondary bile acids improve risk prediction for non‐invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T04%3A16%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Secondary%20bile%20acids%20improve%20risk%20prediction%20for%20non%E2%80%90invasive%20identification%20of%20mild%20liver%20fibrosis%20in%20nonalcoholic%20fatty%20liver%20disease&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Liu,%20A%E2%80%90Na&rft.date=2023-04&rft.volume=57&rft.issue=8&rft.spage=872&rft.epage=885&rft.pages=872-885&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/apt.17362&rft_dat=%3Cproquest_pubme%3E2768244199%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4442-8c0ad6cef56eea2fc5aa4b320362c323cb1d3d0eb9b10d32d7cfe7951ad92cb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2789766043&rft_id=info:pmid/36670060&rfr_iscdi=true |